TNF-α antagonists such as HUMIRA (Adalimumab) and Enbrel (Etanercept) neutralize TNF-α signaling to inhibit excessive macrophage apoptosis, an effect that has been validated in autoimmune disease models, demonstrating the alleviation of tissue inflammation and the maintenance of immune homeostasis (30). Here, TNF is linked to autoimmune disease.